Meta-Analysis of Ferroptosis Inhibitors for Cisplatin-Induced Kidney Injury

58 unique preclinical studies with 265 effect sizes were analyzed in this meta-analysis by Burcu Yuksel, last updated in May 2026. The study synthesizes evidence on renal function and ferroptotic biomarkers to assess the renoprotective potential of natural and synthetic agents. It follows PRISMA 2020 guidelines and uses a three-level random-effects model for data pooling.

Use Cases

• Quantifying the effect of ferroptosis inhibitors on renal function based on BUN and serum creatinine data.
• Analyzing mechanistic drivers of renoprotection based on biomarkers like GPX4, GSH, MDA, 4-HNE, and Fe2+.
• Assessing heterogeneity and potential bias in preclinical studies using the described multilevel meta-regression and PET-PEESE analyses.
• Supporting the clinical development of adjuvants for cisplatin-based chemotherapy based on the quantitative mechanistic consensus.

Strengths

• Analysis is based on 58 unique preclinical studies, providing a substantial evidence base.
• Employs a rigorous three-level random-effects meta-analysis following PRISMA 2020 guidelines.
• Examines multiple outcome types, including renal function and specific ferroptotic biomarkers.

Limitations

• The dataset is a 23.6 KB DOCX file containing the analysis manuscript, not the underlying raw data.
• Row count and column-level documentation for the source data are unknown.
• The authors note significant residual heterogeneity and potential small-study effects, suggesting pooled estimates may be inflated.

Provenance

Source

figshare, author Burcu Yuksel

Collection Method

Systematic review and multilevel meta-analysis of studies from PubMed and Web of Science.

Time Range

Temporal coverage of the included studies is not specified.

Freshness

Last updated 2026-05-04 05:33:13

Geography

Spatial coverage is not specified.